Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Rituximab + Lenalidomide for Relapsed or Refractory Primary CNS Lymphoma (Phase 1/2)
KCT0008545Phase 2Not yet recruiting
- Sponsor
- Celltrion Pharm
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, rituximab, lenalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Celltrion Pharm. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
venetoclaxrituximablenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on KCT0008545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008545.